Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancerM-L Luoma, L Hakamies-Blomqvist, J Sjöström, et al.
Journal of Advanced Nursing|September 1, 2001
Timing of quality of life (QoL) assessments as a source of error in oncological trialsL Hakamies-Blomqvist, M L Luoma, J Sjöström, et al.
The American Journal of Cardiology|June 1, 1978
Unstable angina pectoris: a randomized study of patients treated medically and surgicallyB Pugh, M R Platt, L J Mills, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancerJ Sjöström, C Blomqvist, P Heikkilä, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 2, 2007
Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor HH Jalanko, S Peltonen, A Koskinen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2002
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancerJ Sjöström, J Collan, K von Boguslawski, et al.
Oncogene|November 6, 2007
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancerJ Tommiska, J Bartkova, M Heinonen, et al.
Human Pathology|October 26, 1999
Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomasM L Larramendy, N Mandahl, F Mertens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyN Wilking, E Lidbrink, T Wiklund, et al.
Pageof 19